We are following CDC and employees can ask to be reassigned based on the following:

For this guidance, we are utilizing the CDC guidance for the definition of severe immunocompromised based on medical conditions and medications, which may be found at:

https://wwwnc.cdc.gov/travel/yellowbook/2020/travelers-with-additional-considerations/immunocompromised-travelers

1.AGE: If you are age 65 or older, you may be considered for re-assignment.

2.PREGNANCY: If you are pregnant, you may ask for an assignment that would limit your exposure to confirmed or suspected COVID-19 patients during higher risk procedures, e.g. aerosol generating procedures.

3.UNDERLYING MEDICAL CONDITIONS: If you have any of the following medical conditions, you may be considered “severely immunocompromised”:

•Active leukemia or lymphoma

•Generalized malignancy

•Aplastic anemia

•Graft-versus-host disease

•Congenital immunodeficiency

•Recent radiation therapy or checkpoint inhibitor treatment •Solid-organ transplant recipients and who are on active immunosuppression •CAR-T cell transplant recipients within 2 years of transplantation or still taking immunosuppressive drugs •Hematopoietic stem cell within 2 years of transplantation or still taking immunosuppressive drugs •Human Immunodeficiency Virus infection and a CD4 count < 200 cells/mm3

4.MEDICATIONS: If you are taking any of the medications listed below, you may be considered “severely immunocompromised.”

If you meet any of the above criteria you may request to be voluntarily re-assigned.

List of Medications that Constitute Severe Immunocompromise •High-dose corticosteroids

o   defined as a dose of either >2 mg/kg of body weight or ≥20 mg per day of prednisone or equivalent in people who weigh >10 kg, when administered for ≥2 weeks

•Alkylating agents(such as cyclophosphamide) •Antimetabolites(such as azathioprine, 6-mercaptopurine, methotrexate).

•Transplant-related immunosuppressive drugs(such as cyclosporine, tacrolimus, sirolimus, everolimus, azathioprine, and mycophenolate mofetil) •Cancer chemotherapeutic agents •Tumor necrosis factor (TNF) blockers(e.g. etanercept, adalimumab, certolizumab pegol, golimumab, and infliximab) •Lymphocyte-depleting agents (thymoglobulin or alemtuzumab) •Other biologic agentsthat are immunosuppressive or immunomodulatory including the following:

GENERIC NAME                TRADE NAME

Abatacept                           Orencia

Adalimumab                      Humira

Alemtuzumab                   Campath

Anakinra                              Kineret

Atezolizumab                    Tecentriq

Avelumab                           Bavencio

Basiliximab                          Simulect

Belatacept                          Nulojix

Bevacizumab                     Avastin

Certolizumab pegol         Cimzia

Cetuximab                          Erbitux

Dasatinib                             Sprycel

Dimethyl fumarate          Tecfidera

Etanercept                          Enbrel

Fingolimod                          Gilenya

Glatiramer acetate          Copaxone

Golimumab                        Simponi

Ibritumomab tiuxetan    Zevalin

Ibrutinib                               Imbruvica

Imatinib mesylate            Gleevec, STI 571

GENERIC NAME                TRADE NAME

Infliximab                            Remicade

Interferon alfa                   Pegasys, PegIntron

Interferon beta-1a          Avonex, Rebif

Interferon beta-1b          Betaseron

Natalizumab                       Tsabri

Nivolumab                          Opdivo

Ofatumumab                     Arzerra

Panitumumab                   Vectibix

Pembrolizumab                Keytruda

Lenalidomide                     Revlimid

Rilonacept                           Arcalyst

Rituximab                            Rituxan

Sarilumab                            Kevzara

Secukinumab                     Cosentyx

Sunitinib malate               Sutent

Tocilizumab                        Actemra

Tofacitinib                           Xeljanz

Trastuzumab                      Herceptin

Ustekinumab                     Stelara

Vedolizumab                     Entyvio